Abbimanyu Ojhha has been appointed Chief Financial Officer (CFO) of Cohance Lifesciences, effective October 12, 2026. He brings extensive experience in strategic financial management, corporate finance, business transformation, capital allocation and global operations, with a focus on improving financial performance and creating business value.
Before joining Cohance Lifesciences, Ojhha served as Global CFO and President – Global Finance at Intas Pharmaceuticals. In that role, he was responsible for global finance leadership, drawing on his experience in financial strategy and business performance management.
His earlier leadership positions include Global Head – Office of Business Performance & Management at Viatris and Commercial CFO & Head of Finance for India and Emerging Markets at Mylan. He has also held corporate finance leadership positions at Sun Pharma and Ranbaxy.
Across these roles, Ojhha has developed expertise in global financial strategy, mergers and acquisitions, operational efficiency and business performance management. His experience spans financial leadership across pharmaceutical businesses and markets, including responsibilities related to commercial finance and corporate finance.
At Cohance Lifesciences, Ojhha will bring this background to the company’s financial leadership, supporting strategic financial management, capital allocation and operational performance. His appointment adds an experienced finance leader with a background in pharmaceutical industry operations and global business management.
Ojhha’s appointment takes effect on October 12, 2026. The announcement did not provide further details about changes to the company’s finance strategy or his specific priorities in the new role.
 of Cohance Lifesciences, effective October 12, 2026...){kind=link}